ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2545

Physicians, but Not Patients, Agree That EULAR Good Response Indicates Remission after 12 Weeks Treatment of Early Rheumatoid Arthritis

Samina A. Turk1, Dirkjan van Schaardenburg1,2, Linda A. Rasch3, Véronique Lugt1, Willem F. Lems1,3, Mike T. Nurmohamed1,4 and Lilian van Tuyl3, 1Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, 2Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, 3Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, 4Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Early Rheumatoid Arthritis, patient outcomes and remission

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The Disease Activity Score (DAS) and the European League Against Rheumatism (EULAR) response criteria are commonly used to describe disease activity in Rheumatoid Arthritis (RA) patients(1). This study investigates the relationship between remission perceived by physicians versus patients according to the EULAR response criteria.

Methods: Consecutive RA patients with high disease activity and/or unfavourable prognostic factors and no prior treatment were investigated. Patients were treated with methotrexate and prednisolone (week 1: 30 mg, week 2: 20  mg, week 3: 15 mg, week 4-8: 10 mg, week 9-12: 7,5 mg). After 12 weeks of treatment the EULAR response was determined, according to the DAS44. Physician perceived remission was defined as a physician global assessment ≤ 20  on a visual analogue scale (VAS), phrased: “How active do you think the rheumatoid arthritis of your patient is today?”. For patient perceived remission the following question was phrased: “Would you say that, at this moment, your disease activity is as good as gone? (yes/no)(2).

Results: In 75 early RA patients the mean (SD) DAS44 decreased from 3.4 (1.2) to 1.5 (1.0) after 12 weeks of therapy. The number of good, moderate and none EULAR responders were 54 (72%), 14 (19%) and 7 (9%) respectively. After 12 weeks 72% of the physicians perceived remission as well as 72% of the patients, see figure 1. The spearman’s rho test showed significant correlations between the EULAR response versus perception of physicians, the EULAR response versus the perception of patients and the perception of patients versus physicians, respectively r=0.645 (p<0.001), r=0.393 (p=0.001) and r=0.267 (p=0.036). In 61% of the good EULAR responders the physician as well as the patient perceived remission, but in 33% only the physician perceived remission, see figure 2. Patients who did not perceive remission had a significantly different mean (SD) DAS44 of 1.4 (0.5) compared to 0.9 (0.5) in the patients who perceived remission (p=0.001). The difference in DAS44 is caused by tender joint count (TJC) and patient global (PG) but not by swollen joint count or erythrocyte sedimentation rate.

Conclusion: There is a significant correlation between EULAR response and both physicians and patients perceived remission in early RA patients. However, 33% of the patients with a good EULAR response and physician perceived remission, perceive no remission themselves. These patients had a significantly higher DAS44, caused by a higher TJC and PG. Literature:

1)       Van Riel et al. Clin Exp Rheumatol 2005 Sep;23:S93-99

2)       Van Tuyl LH et al.,  Ann Rheum Dis 2015 Jun;74(6):1004-10.  

   


Disclosure: S. A. Turk, None; D. van Schaardenburg, None; L. A. Rasch, None; V. Lugt, None; W. F. Lems, Pfizer Inc, 2,BMS, 8,Abbvie, 8,Lilly, 8,Pfizer Inc, 8,Roche Pharmaceuticals, 8; M. T. Nurmohamed, None; L. van Tuyl, None.

To cite this abstract in AMA style:

Turk SA, van Schaardenburg D, Rasch LA, Lugt V, Lems WF, Nurmohamed MT, van Tuyl L. Physicians, but Not Patients, Agree That EULAR Good Response Indicates Remission after 12 Weeks Treatment of Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/physicians-but-not-patients-agree-that-eular-good-response-indicates-remission-after-12-weeks-treatment-of-early-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/physicians-but-not-patients-agree-that-eular-good-response-indicates-remission-after-12-weeks-treatment-of-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology